TY - JOUR
T1 - Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation
AU - The Trifecta Investigators
AU - Halloran, Philip F.
AU - Reeve, Jeff
AU - Madill-Thomsen, Katelynn S.
AU - Kaur, Navchetan
AU - Ahmed, Ebad
AU - Cantos, Carlos
AU - Al Haj Baddar, Nour
AU - Demko, Zachary
AU - Liang, Nathan
AU - Swenerton, Ryan K.
AU - Zimmermann, Bernhard G.
AU - Van Hummelen, Paul
AU - Prewett, Adam
AU - Rabinowitz, Matthew
AU - Tabriziani, Hossein
AU - Gauthier, Phil
AU - Billings, Paul
AU - Fryc, Justyna
AU - Naumnik, Beata
AU - Bromberg, Jonathan
AU - Weir, Matt
AU - Costa, Nadiesda
AU - Brennan, Daniel
AU - Kant, Sam
AU - Viswanathan, Vignesh
AU - Samaniego-Picota, Milagros
AU - Francis, Iman
AU - Patel, Anita
AU - Dȩbska-Ślizień, Alicja
AU - Konopa, Joanna
AU - Chamienia, Andrzej
AU - Wiȩcek, Andrzej
AU - Piecha, Grzegorz
AU - Veceric-Haler, Željka
AU - Arnol, Miha
AU - Kojc, Nika
AU - Glyda, Maciej
AU - Smykal-Jankowiak, Katarzyna
AU - Viklicky, Ondrej
AU - Hruba, Petra
AU - Bloudíčkova, Silvie Rajnochová
AU - Slatinská, Janka
AU - Miglinas, Marius
AU - Myślak, Marek
AU - Mazurkiewicz, Joanna
AU - Gryczman, Marta
AU - Domański, Leszek
AU - Kamel, Mahmoud
AU - Perkowska-Ptasińska, Agnieszka
AU - Dȩborska-Materkowska, Dominika
AU - Ciszek, Michal
AU - Durlik, Magdalena
AU - Pączek, Leszek
AU - Grenda, Ryszard
AU - Banasik, Miroslaw
AU - Knotek, Mladen
AU - Vucur, Ksenija
AU - Jurekovic, Zeljka
AU - Müller, Thomas
AU - Schachtner, Thomas
AU - Malone, Andrew
AU - Alhamad, Tarek
AU - Jittirat, Arksarapuk
AU - Poggio, Emilio
AU - Fatica, Richard
AU - Zaky, Ziad
AU - Chow, Kevin
AU - Hughes, Peter
AU - Anand, Sanjiv
AU - Gupta, Gaurav
AU - Kamal, Layla
AU - Kumar, Dhiren
AU - Moinuddin, Irfan
AU - Bobba, Sindhura
N1 - Funding Information:
The Trifecta study is an investigator-initiated study supported by a grant from Natera to Transcriptome Sciences Inc/Alberta Transplant Applied Genomics Centre. The Microarray biopsy assessment project is supported in part by a licensing agreement with One Lambda/Thermo Fisher Scientific.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Background. Donor-derived cell-free DNA (dd-cfDNA) fraction and quantity have both been shown to be associated with allograft rejection. The present study compared the relative predictive power of each of these variables to the combination of the two, and developed an algorithm incorporating both variables to detect active rejection in renal allograft biopsies. Methods. The first 426 sequential indication biopsy samples collected from the Trifecta study (ClinicalTrials.gov # NCT04239703) with microarray-derived gene expression and dd-cfDNA results were included. After exclusions to simulate intended clinical use, 367 samples were analyzed. Biopsies were assessed using the molecular microscope diagnostic system and histology (Banff 2019). Logistic regression analysis examined whether combining dd-cfDNA fraction and quantity adds predictive value to either alone. The first 149 sequential samples were used to develop a two-threshold algorithm and the next 218 to validate the algorithm. Results. In regression, the combination of dd-cfDNA fraction and quantity was found to be significantly more predictive than either variable alone (P = 0.009 and P < 0.0001). In the test set, the area under the receiver operating characteristic curve of the two-variable system was 0.88, and performance of the two-threshold algorithm showed a sensitivity of 83.1% and specificity of 81.0% for molecular diagnoses and a sensitivity of 73.5% and specificity of 80.8% for histology diagnoses. Conclusions. This prospective, biopsy-matched, multisite dd-cfDNA study in kidney transplant patients found that the combination of dd-cfDNA fraction and quantity was more powerful than either dd-cfDNA fraction or quantity alone and validated a novel two-threshold algorithm incorporating both variables.
AB - Background. Donor-derived cell-free DNA (dd-cfDNA) fraction and quantity have both been shown to be associated with allograft rejection. The present study compared the relative predictive power of each of these variables to the combination of the two, and developed an algorithm incorporating both variables to detect active rejection in renal allograft biopsies. Methods. The first 426 sequential indication biopsy samples collected from the Trifecta study (ClinicalTrials.gov # NCT04239703) with microarray-derived gene expression and dd-cfDNA results were included. After exclusions to simulate intended clinical use, 367 samples were analyzed. Biopsies were assessed using the molecular microscope diagnostic system and histology (Banff 2019). Logistic regression analysis examined whether combining dd-cfDNA fraction and quantity adds predictive value to either alone. The first 149 sequential samples were used to develop a two-threshold algorithm and the next 218 to validate the algorithm. Results. In regression, the combination of dd-cfDNA fraction and quantity was found to be significantly more predictive than either variable alone (P = 0.009 and P < 0.0001). In the test set, the area under the receiver operating characteristic curve of the two-variable system was 0.88, and performance of the two-threshold algorithm showed a sensitivity of 83.1% and specificity of 81.0% for molecular diagnoses and a sensitivity of 73.5% and specificity of 80.8% for histology diagnoses. Conclusions. This prospective, biopsy-matched, multisite dd-cfDNA study in kidney transplant patients found that the combination of dd-cfDNA fraction and quantity was more powerful than either dd-cfDNA fraction or quantity alone and validated a novel two-threshold algorithm incorporating both variables.
UR - http://www.scopus.com/inward/record.url?scp=85137557079&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000004212
DO - 10.1097/TP.0000000000004212
M3 - Article
C2 - 35765145
AN - SCOPUS:85137557079
SN - 0041-1337
VL - 106
SP - 2435
EP - 2442
JO - Transplantation
JF - Transplantation
IS - 12
ER -